Letter to the editorBiologic IgG level in primary immunodeficiency disease: The IgG level that protects against recurrent infection
References (7)
- et al.
Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients
J Pediatr
(1999) Goals of therapy in antibody deficiency syndromes
J Allergy Clin Immunol
(1999)- et al.
Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency
Int Immunopharmacol
(2004)
There are more references available in the full text version of this article.
Cited by (149)
Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions
2022, Journal of Allergy and Clinical Immunology: In PracticeTreatment of primary immunodeficiencies and inborn errors of immunity
2022, Allergic and Immunologic Diseases: A Practical Guide to the Evaluation, Diagnosis and Management of Allergic and Immunologic DiseasesImmunoglobulin Replacement Therapy
2022, Encyclopedia of Infection and Immunity
Disclosure of potential conflict of interest: V. R. Bonagura has received support from the National Institutes of Health and has served as a member for CST. The rest of the authors have declared that they have no conflict of interest.
Copyright © 2008 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.